Atkinson BA, Bocanegra R, Graybill JR; National Conference on Human Retroviruses and Related Infections.
Program Abstr Second Natl Conf Hum Retrovir Relat Infect Natl Conf Hum Retrovir Relat Infect 2nd 1995 Wash DC. 1995 Jan 29-Feb 2; 76.
The Univ of TX Hlth Sci Ctr at San Antonio, Audie L Murphy Mem Vet Hosp San Antonio, TX.
M. haemophilum is a recently recognized pathogen in AIDS patients. There is no standard approach to treatment. We developed an animal model of disseminated M. haemophilum infection in athymic mice. This is characterized by disseminated infection in spleen and lungs following a subcutaneous (SQ) challenge of M. haemophilum into the shoulder of immune deficient mice. We compared the effectiveness of ciprofloxicin (100 mg/kg IV), rifabutin (40 mg/kg PO), clarithromycin (200 mg/kg PO) and rifabutin and clarithromycin combined. Infection (skin lesions & dissemination to spleen & lungs but not blood) was present in nu/nu but not in nu/+ or ICR mice. Treatment was begun 2 weeks after SQ challenge and continued for 4 weeks. Animals were sacrificed at 2, 4, and 8 weeks and the CFU/gm spleen was determined. At 4 weeks, clarithromycin, rifabutin and the combination of clarithromycin + rifabutin effectively cleared the spleen tissue burden; ciprofloxacin was ineffective. Four weeks after the completion of treatment, only the rifabutin + clarithromycin treated mice were infection free. When mice were treated with clarithromycin + rifabutin for 20 weeks and then sacrificed, the spleen burden was effectively cleared. On followup 4 weeks after the completion of therapy, no organisms were recovered from the spleen, skin or blood. Treatment regimens may require long term therapy with rifabutin and clarithromycin. Ciprofloxacin alone appears to be ineffective in treating M. haemophilum.
Publication Types:
Keywords:
- Animals
- Ciprofloxacin
- Clarithromycin
- Humans
- Mice
- Mice, Nude
- Mycobacterium Infections
- Rifabutin
Other ID:
UI: 102213096
From Meeting Abstracts